## IN THE CLAIMS

Please cancel pending Claims 27, 29 to 34, 36, 37, 53, 61 and 64 to 67 without prejudice. Please amend Claims 28 and 35 and add new Claims 75 to 79 as follows:

- 1-26. (Withdrawn)
- 27. (Cancelled)
- inhibiting or preventing restenosis of an artery resulting from vascular injury angioplasty in a human subject, the method comprising placing an endolumenal stent in the artery at the site of the angioplasty, wherein the stent comprises eplerenone administering an aldosterone antagonist to a human subject susceptible to or suffering from said restenosis, wherein said aldosterone antagonist is administered in an amount that is therapeutically effective in suppressing said restenosis.
  - 29-34. (Cancelled)
- 35. (Currently Amended) The method of Claim  $\frac{31}{28}$  wherein the angioplastied artery is a coronary artery.
  - 36-37. (Cancelled)
  - 38-52. (Withdrawn)
  - 53. (Cancelled)
  - 54-60. (Withdrawn)
  - 61. (Cancelled)
  - 62-63. (Withdrawn)

- 64-67. (Cancelled)
- 68-74. (Withdrawn)
- 75. (New) The method of Claim 28 wherein eplerenone is present on the surface of the stent.
- 76. (New) The method of Claim 28 wherein eplerenone is coated on, absorbed on, or affixed to the stent.
- 77. (New) The method of Claim 28 wherein eplerenone is present in or on the matrix of the stent.
- 78. (New) The method of Claim 28 wherein eplerenone is in the form of an extended release composition.
- 79. (New) The method of Claim 28 further comprising a second active ingredient.

\* \* \*